169 related articles for article (PubMed ID: 1495694)
1. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3.
Jacobs IJ; Oram DH; Bast RC
Obstet Gynecol; 1992 Sep; 80(3 Pt 1):396-9. PubMed ID: 1495694
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer.
Einhorn N; Sjövall K; Knapp RC; Hall P; Scully RE; Bast RC; Zurawski VR
Obstet Gynecol; 1992 Jul; 80(1):14-8. PubMed ID: 1603484
[TBL] [Abstract][Full Text] [Related]
4. Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening.
Cane P; Azen C; Lopez E; Platt LD; Karlan BY
Gynecol Oncol; 1995 May; 57(2):240-5. PubMed ID: 7729742
[TBL] [Abstract][Full Text] [Related]
5. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
7. [Value of the TAG-72 (CA 72-4) tumor marker in primary diagnosis of ovarian carcinoma. A comparison with the established CA-125 marker].
Zeimet AG; Guadagni F; Marth C; Amato T; Müller-Holzner E; Huter O; Daxenbichler G; Dapunt O
Geburtshilfe Frauenheilkd; 1995 Apr; 55(4):195-9. PubMed ID: 7789707
[TBL] [Abstract][Full Text] [Related]
8. [Predictive value of the tumor marker combination CA-125 and beta-2-microglobulin in ovarian cancer].
Hernádi Z; Molnár V; Juhász B; Pólka R; Margitai B
Zentralbl Gynakol; 1992; 114(1):6-9. PubMed ID: 1585745
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing serum CA 125 levels in normal women.
Grover S; Quinn MA; Weideman P; Koh H
Obstet Gynecol; 1992 Apr; 79(4):511-4. PubMed ID: 1553167
[TBL] [Abstract][Full Text] [Related]
10. The serum concentrations of TAG-72 antigen measured with CA 72-4 IRMA in patients with ovarian carcinoma. Preliminary data.
Gadducci A; Ferdeghini M; Ceccarini T; Prontera C; Facchini V; Bianchi R; Fioretti P
J Nucl Med Allied Sci; 1989; 33(1):32-6. PubMed ID: 2746365
[TBL] [Abstract][Full Text] [Related]
11. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer.
Oehler MK; Sütterlin M; Caffier H
Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185
[TBL] [Abstract][Full Text] [Related]
12. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women.
Skates SJ; Menon U; MacDonald N; Rosenthal AN; Oram DH; Knapp RC; Jacobs IJ
J Clin Oncol; 2003 May; 21(10 Suppl):206s-210s. PubMed ID: 12743136
[TBL] [Abstract][Full Text] [Related]
13. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer.
Suzuki M; Ohwada M; Aida I; Tamada T; Hanamura T; Nagatomo M
Obstet Gynecol; 1993 Dec; 82(6):946-50. PubMed ID: 8233270
[TBL] [Abstract][Full Text] [Related]
14. Saliva and serum CA 125 assays for detecting malignant ovarian tumors.
Chen DX; Schwartz PE; Li FQ
Obstet Gynecol; 1990 Apr; 75(4):701-4. PubMed ID: 2179784
[TBL] [Abstract][Full Text] [Related]
15. Preoperative serum tumor-associated antigen levels in women with pelvic masses.
Soper JT; Hunter VJ; Daly L; Tanner M; Creasman WT; Bast RC
Obstet Gynecol; 1990 Feb; 75(2):249-54. PubMed ID: 2300353
[TBL] [Abstract][Full Text] [Related]
16. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
[TBL] [Abstract][Full Text] [Related]
17. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
[TBL] [Abstract][Full Text] [Related]
18. [Tumor markers in epithelial ovarian cancer].
Di Cocco B; Calabretta F; Alghisi F; Salesi N; Bossone G
Minerva Ginecol; 2003 Aug; 55(4):327-32. PubMed ID: 14581857
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous measurement of CA 125, CA 19-9, tissue polypeptide antigen, and immunosuppressive acidic protein to predict recurrence of ovarian cancer.
Kamiya N; Mizuno K; Kawai M; Kano T; Furuhashi Y; Tomoda Y
Obstet Gynecol; 1990 Sep; 76(3 Pt 1):417-21. PubMed ID: 2381619
[TBL] [Abstract][Full Text] [Related]
20. CA 72-4 measurement of tumor-associated glycoprotein 72 (TAG-72) as a serum marker in the management of gastric carcinoma.
Guadagni F; Roselli M; Amato T; Cosimelli M; Perri P; Casale V; Carlini M; Santoro E; Cavaliere R; Greiner JW
Cancer Res; 1992 Mar; 52(5):1222-7. PubMed ID: 1737383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
